EUVIMEDEUVIMED entdecken
Crossref

Multifunctional nanodrug for simultaneously combating chemoresistance and immunosuppression in Fusobacterium nucleatum-associated colorectal cancer

Xiaohui Li, Mengdi Wu, Yu Wu, Youtao Xin, Linran Gao, Mahmoud Elsabahy, Xuan Wang, Jimin Zhang, Xiongwei Qu, Hui Gao

Acta Biomaterialia · 2025

DOI: 10.1016/j.actbio.2025.02.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Xiaohui Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Separation Membranes and Membrane Processes& Key Laboratory of Hollow Fiber Membrane Materials and Membrane Processes (MOE) &…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fusobacterium nucleatum, Drug Resistance, Neoplasm, Nanoparticles. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fusobacterium nucleatum (Fn) infection in colorectal cancer (CRC) induces chemoresistance and creates an immunosuppressive tumor microenvironment, compromising the efficacy of conventional chemotherapy. To address these challenges, a multifunctional MPLO@HA nanodrug was developed by conjugating metformin (Met), oxaliplatin (OxPt), and lauric acid (LA) onto oligomethyleneimine, subsequently complexed with hyaluronic acid (HA). The MPLO@HA nanodrug is designed to target Fn-infected CRC, offering multiple mechanisms for enhanced therapeutic outcomes. The nanodrug features a multi-stimuli responsive structure that enables precise and controlled release at the tumor site, responsive to pH, glutathione, and hyaluronidase levels. The enhanced positive charge of self-assembled nanodrug combined with Met effectively eradicates both extracellular and intracellular Fn, overcoming Fn-induced chemoresistance. Furthermore, incorporating Met improves the efficacy of chemotherapy by sensitizing CRC cells to treatment. The immunomodulatory properties of the MPLO@HA nanodrug promote immunogenic cell death, repolarize macrophages from the M2 to the M1 phenotype, and reduce the levels of regulatory T cells and myeloid-derived suppressor cells. By integrating antimicrobial, chemotherapeutic, and immunomodulatory capabilities, the MPLO@HA nanodrug offers a promising and comprehensive approach to combating Fn-induced chemoresistance and immunosuppression in CRC. This strategy could also provide a foundation for developing treatments for other cancers associated with bacterial infections. STATEMENT OF SIGNIFICANCE: Fusobacterium nucleatum (Fn) infection in colorectal cancer (CRC) induces chemoresistance and creates an immunosuppressive tumor microenvironment, severely compromising treatment efficacy. Current therapies face challenges in addressing these issues due to the complex interactions between bacterial infection and tumor development. Our study introduces a multifunctional nanodrug, MPLO@HA, which integrates metformin, oxaliplatin, lauric acid, and hyaluronic acid into a multi-responsive nanodrug system. This nanodrug simultaneously combats bacterial infection, chemoresistance, and immunosuppression in Fn-associated CRC. MPLO@HA demonstrates synergistic effects by eradicating both extracellular and intracellular Fn, enhancing chemosensitivity, and modulating the tumor immune microenvironment. This comprehensive approach offers a promising strategy to overcome Fn-induced treatment barriers, potentially improving outcomes for patients with Fn-infected CRC and opening new avenues in bacteria-associated cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsFusobacterium nucleatumDrug Resistance, NeoplasmNanoparticlesFusobacterium InfectionsImmunosuppression TherapyHumansAnimalsHyaluronic AcidOxaliplatinTumor MicroenvironmentMiceCell Line, TumorMetformin

Stichwörter der Autor:innen

ChemoresistanceColorectal cancerFusobacterium nucleatumImmunomodulationMetformin

Substanzen

Hyaluronic AcidOxaliplatinMetformin

Autor:innen und Institutionen

  • State Key Laboratory of Separation Membranes and Membrane Processes& Key Laboratory of Hollow Fiber Membrane Materials and Membrane Processes (MOE) & Tianjin Key Laboratory of Hollow Fiber Membrane Materials and Process…
  • School of Biotechnology, Badr University in Cairo, Badr City, Cairo, 11829, Egypt.
  • Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin Institute of Digestive Diseases, Tianjin Key Laboratory of Digestive Diseases, Tianjin, 300052, China.
  • Hebei Key Laboratory of Functional Polymers, School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin, 300401, China.

Förderung

  • National Natural Science Foundation of China
  • Tianjin Municipal Natural Science Foundation

Zitieren

APA

Li, X., Wu, M., Wu, Y., Xin, Y., Gao, L., Elsabahy, M., Wang, X., Zhang, J., Qu, X., & Gao, H. (2025). Multifunctional nanodrug for simultaneously combating chemoresistance and immunosuppression in Fusobacterium nucleatum-associated colorectal cancer. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.02.013

Vancouver

Li X, Wu M, Wu Y, Xin Y, Gao L, Elsabahy M, et al. Multifunctional nanodrug for simultaneously combating chemoresistance and immunosuppression in Fusobacterium nucleatum-associated colorectal cancer. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.02.013

BibTeX
@article{Li2025,
  author = {Li, Xiaohui and Wu, Mengdi and Wu, Yu and Xin, Youtao and Gao, Linran and Elsabahy, Mahmoud and Wang, Xuan and Zhang, Jimin and Qu, Xiongwei and Gao, Hui},
  title = {Multifunctional nanodrug for simultaneously combating chemoresistance and immunosuppression in Fusobacterium nucleatum-associated colorectal cancer},
  journal = {Acta Biomaterialia},
  year = {2025},
  doi = {10.1016/j.actbio.2025.02.013}
}
Kostenlos starten →